Loading...
•
Mar 31, 2022
Enanta Pharmaceuticals Q2 2022 Earnings Report
Reported financial results for the fiscal second quarter ended March 31, 2022.
Key Takeaways
Enanta Pharmaceuticals reported a revenue of $18.7 million and a net loss of $33.6 million, or $1.63 per diluted common share, for the three months ended March 31, 2022. The company's cash, cash equivalents and short-term and long-term marketable securities totaled $322.5 million at March 31, 2022.
Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter
Received Fast Track Designation for EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19; Expects Preliminary Data From a Phase 1 Study of EDP-235 This Quarter
On Track to Initiate a Phase 1 Study of EDP-323, an RSV L-Protein Inhibitor, in the Second Half of 2022
Royalty Revenue for the Quarter was $18.7 Million
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs for at least the next two years.